Bilge Tuncer

Dr. Bilge Tuncer

orcid

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2005 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Closed access
PDF file
BTBilge Tuncer
Bilge Tuncer
CBC. A. Babacan
C. A. Babacan
MAM. Arslan
M. Arslan

1 January 2007
Verified
Journal Article
Closed access
BTBilge Tuncer
Bilge Tuncer
ABAvni Babacan
Avni Babacan
MAMustafa Arslan
Mustafa Arslan

17 April 2024 in Journal of Burn Care & Research
Verified
Journal Article
Closed access
PDF file
MAMerve Akın
Merve Akın
BTBilge Tuncer
Bilge Tuncer
AAAli Emre Akgün
Ali Emre Akgün
EEEzgi Erkılıç
Ezgi Erkılıç
Pulmonary insufficiency is the primary cause of death in cases of major burns accompanied by inhalation damage. It is important to consider the impact on the face and neck in flame burns. Early implementation of bronchial hygiene measures and oxygenation treatment in inhalation injury can reduce mortality. This case series presents the effects of high-flow nasal oxygen (HFNO) application on patient outcomes in major burns and inhalation injury. This report discusses 3 different patients. One patient, a 29-year-old male with 35% TBSA burns, received HFNO treatment for inhalation injury on the sixth day after the trauma. After 72 hours of HFNO application, the patient’s pulmonary symptoms improved. The second patient had 60% TBSA burns and developed respiratory distress symptoms on the fifth day after the trauma. After 7 days of HFNO application, all symptoms and findings of acute respiratory distress syndrome (ARDS) were resolved. HFNO has been used for the treatment of ARDS related to major burn (60% of burned TBSA) in a 28-year-old patient, and improvement was achieved. The use of HFNO in pulmonary insufficiency among burn patients has not been reported previously. This series of patient cases demonstrates the successful application of HFNO in treating inhalation injury and burn-related ARDS. However, further clinical studies are necessary to increase its clinical utilization.

1 August 2004 in Pediatric Anesthesia
Verified
Journal Article
Closed access
PDF file
NCNedim Cekmen
Nedim Cekmen
AKAySegul Zengin Kordan
AySegul Zengin Kordan
BTBilge Tuncer
Bilge Tuncer
IGIrfan Gungor
Irfan Gungor
MAMehmet Akcabay
Mehmet Akcabay

1 April 2006
Verified
Journal Article
Closed access
Mustafa ArslanMustafa Arslan
Mustafa Arslan
BTBilge Tuncer
Bilge Tuncer
ABAvni Babacan
Avni Babacan
FTFerit Taneri
Ferit Taneri
YKYener Karadenizli
Yener Karadenizli
BEBahadir Ege
Bahadir Ege

19 February 2023 in Anaesthesia, Pain & Intensive Care
Verified
Journal Article
Open access
PDF file
BTBilge Tuncer
Bilge Tuncer
EEEzgi Erkılıç
Ezgi Erkılıç
GIGurkan Ilhan
Gurkan Ilhan
MAMerve Akin
Merve Akin
OKOrhan Kanbak
Orhan Kanbak
Toxic epidermal necrolysis (TEN), is an acute, life-threatening emergent disease involving the skin and mucous membranes with serious systemic complications. It is characterized by widespread epidermal sloughing. Drugs are the most common triggers of TEN, but infection, vaccination, radiation therapy and malignant neoplasms can all induce it in susceptible patients. We report two cases in whom a hair dye and a COVID-19 vaccine (BioNTech®, Pfizer) were believed to be the causative agents. These patients have to undergo repeated debridements of the necrotic tissue. In this manuscript the anesthetic management of TEN patients is discussed. Detailed preoperative evaluation, aggressive fluid and electrolyte replacement, avoidance of hypothermia during debridement, minimizing anesthetic agents and limiting traumatic procedures are key points in the management. Abbreviations: BUN: blood urea nitrogen; BSA: Body surface area; Cr: Creatinine; OR: Operating room; SJS: Stevens-Johnson Syndrome; TEN: Toxic epidermal necrolysis Key words: Anesthesia; COVID-19; Toxic epidermal necrolysis; Vaccine Citation: Bilge B, Erkilic E, İlhan G, Akin M, Kanbak O. Anesthetic management of toxic epidermal necrolysis: a report of two cases. Anaesth. pain intensive care 2022;27(1):135−138; DOI: 10.35975/apic.v27i1.2113 Received: November 22, 2022; Reviewed: November 29, 2022; Accepted: December 02, 2022